Tepotinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), HIRA (South Korea) and NICE (England), among others, recommended or restricted tepotinib, while CIPM (Spain) and NYE METODER (Norway) did not recommend it.
Assessment has run over 5.1 years, from 2021 at PBAC (Australia) to 24 Aug 2026 at AOTMIT (Poland).
No assessment is on file from HAS (France) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 5 of 11 records date from 2023 or later.
4 distinct indication wordings are recorded for tepotinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 11 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess tepotinib, in 2021; AOTMIT (Poland) did not open a file until 24 Aug 2026 — a wide spread of 5.1 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 5 of 11 dated records fall in 2022 alone.
Restriction is doing real work here: 2 of 8 decisive outcomes narrowed tepotinib to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland) and TLV (Sweden).
PBAC (Australia) is the only agency to have returned to tepotinib, recording 2 separate entries.
10 of the 18 agencies in this archive hold a record for tepotinib.
The full ledger for tepotinib reads 4 recommended, 2 restricted, 2 not recommended and 1 no benefit, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 15 Mar 2026 | I monoterapi til behandling av voksne pasienter med avansert ikke-småcellet lungekreft (NSCLC) med mutasjoner som fører … | not introduced | source |
| HIRA (South Korea) | 5 Dec 2024 | MET 엑손 14 결손 국소 진행성 또는 전이성 비소세포폐암의 치료 | reimbursement appropriate | source |
| TLV (Sweden) | 21 Apr 2023 | Tepmetko ingår i högkostnadsskyddet med begränsad subvention | restricted subsidy | source |
| SMC (Scotland) | 16 Jan 2023 | For treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping… | accepted | source |
| CIPM (Spain) | 24 Nov 2022 | Indicación terapéutica autorizada: TEPMETKO en monoterapia está indicado para el tratamiento de pacientes adultos con cá… | not financed by the SNS · art. 92 c, d | source |
6 further decisions for tepotinib, across 5 agencies, are not shown here. They include the most recent record on file, 24 Aug 2026 from AOTMIT (Poland); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- sotorasib — divergent outcome (recommended vs not recommended) on a shared indication
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
Coverage: 11 decisions for tepotinib from 10 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.